DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 26, Issue 4, 2016, Pages 273-284

  Bonora, Enzo ^a   Cigolini, Massimo ^a  

^a UNIVERSITY AND HOSPITAL TRUST OF VERONA   (Italy)

Author keywords

Antidiabetic agents; Cardiovascular disease; Dipeptidyl peptidase 4 inhibitors; Type 2 diabetes mellitus

Indexed keywords

ACARBOSE; ALOGLIPTIN; CANAGLIFLOZIN; DAPAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EMPAGLIFLOZIN; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; LINAGLIPTIN; MEGLITINIDE; METFORMIN; PIOGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; VILDAGLIPTIN; ANTIDIABETIC AGENT; PIPERIDINE DERIVATIVE; URACIL;

ANTIDIABETIC ACTIVITY; BLOOD GLUCOSE MONITORING; CARDIOVASCULAR DISEASE; CAROTID ATHEROSCLEROSIS; FOOD AND DRUG ADMINISTRATION; GLUCAGON RELEASE; HOSPITALIZATION; HYPERGLYCEMIA; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; VASODILATATION; ANALOGS AND DERIVATIVES; BIOASSAY; CARDIOVASCULAR DISEASES; COMPLICATION; DIABETES MELLITUS, TYPE 2; HUMAN; META ANALYSIS (TOPIC); OBSERVATIONAL STUDY; PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR;

CARDIOVASCULAR DISEASES; CLINICAL TRIALS, PHASE III AS TOPIC; CLINICAL TRIALS, PHASE IV AS TOPIC; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; ENDPOINT DETERMINATION; HUMANS; HYPOGLYCEMIC AGENTS; LINAGLIPTIN; META-ANALYSIS AS TOPIC; OBSERVATIONAL STUDIES AS TOPIC; PIPERIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SITAGLIPTIN PHOSPHATE; URACIL;

EID: 84962077052     PISSN: 09394753     EISSN: 15903729     Source Type: Journal    
DOI: 10.1016/j.numecd.2016.03.002     Document Type: Review

References (179)

1. International Diabetes Federation IDF diabetes atlas 2013, IDF, Brussels. 6th ed.
2. Caspersen C.J., Thomas G.D., Boseman L.A., Beckles G.L., Albright A.L. Aging, diabetes and the public health system in the United States. Am J Public Health 2012, 102:1482-1497.
3. Jönsson B., CODE-2 Advisory Board Revealing the cost of type II diabetes in Europe. Diabetologia 2002, 45:S5-S12.
4. Bruno G., Picariello R., Petrelli A., Panero F., Costa G., Cavallo-Perin P., et al. Direct costs in diabetic and non diabetic people: the population-based Turin study, Italy. Nutr Metab Cardiovasc Dis 2012, 22:684-690.
5. Marchesini G., Forlani G., Rossi E., Berti A., De Rosa M. The direct economic cost of pharmacologically-treated diabetes in Italy-2006. The ARNO observatory. Nutr Metab Cardiovasc Dis 2011, 21:339-346. ARNO Working Group.
6. De Marco R., Locatelli F., Zoppini G., Verlato G., Bonora E., Muggeo M. Cause-specific mortality in type 2 diabetes mellitus. The Verona Diabetes Study. Diabetes Care 1999, 22:756-761.
7. Barnett K.N., Ogston S.A., McMurdo M.E., Morris A.D., Evans J.M. A 12-year-follow-up study of all-cause and cardiovascular mortality among 10,532 people with newly diagnosed type 2 diabetes in Tayside, Scotland. Diabet Med 2010, 27:1124-1129.
8. Franco O.H., Steyeberg E.W., Hu F.B., Mackenbach J., Nusselder W. Associations of diabetes mellitus with total life expectancy and life expectancy with and without cardiovascular disease. Arch Intern Med 2007, 167:1145-1151.
9. Seshasai S.R., Kaptoge S., Thompson A., Di Angelantonio E., Gao P., Sarwar N., et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011, 364:829-841. Emerging Risk Factors Collaboration.
10. Preis S.R., Hwang S.-J., Coady S., Pencin M.J., D'Agostino R.B., Savage P.J., et al. Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation 2009, 119:1728-1733.
11. Sattar N. Revisiting the links between glycaemia, diabetes and cardiovascular disease. Diabetologia 2013, 56:686-695.
12. Norhammar A., Schenck-Gustafsson K. Type 2 diabetes and cardiovascular disease in women. Diabetologia 2013, 56:1-9.
13. Nichols G.A., Joshua-Gotlib S., Parasuraman S. Glycemic control and risk of cardiovascular disease hospitalization and all-cause mortality. J Am Coll Cardiol 2013, 62:121-127.
14. Sarwar N., Gao P., Seshasai S.R., Gobin R., Kaptoge S., Di Angelantonio E., et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta analysis of 102 prospective studies. Lancet 2010, 375:2215-2222. Emerging Risk Factors Collaboration.
15. Khaw K.T., Wareham N., Bingham S., Luben R., Welch A., Day N. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med 2004, 141:413-420.
16. DECODE Study Group Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases?. Diabetes Care 2003, 26:688-696. European Diabetes Epidemiology Group.
17. Moss S.E., Klein R., Klein B.E., Meuer S.M. The association of glycemia and cause-specific mortality in a diabetic population. Arch Intern Med 1994, 154:2473-2479.
18. Stratton I.M., Adler A.I., Neil H.A., Matthews D.R., Manley S.E., Cull C.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000, 321:405-412.
19. Selvin E., Coresh J., Golden S.H., Brancati F.L., Folsom A.R., Steffes M.W. Glycemic control and coronary heart disease risk in persons with and without diabetes: the atherosclerosis risk in communities study. Arch Intern Med 2005, 165:1910-1916.
20. Bonora E., Corrao G., Bagnardi V., Ceriello A., Comaschi M., Montanari P., et al. Prevalence and correlates of post-prandial hyperglycemia in a large sample of patients with type 2 diabetes mellitus. Diabetologia 2006, 49:846-854.
21. Bonora E., Calcaterra F., Lombardi S., Bonfante N., Formentini G., Bonadonna R.C., et al. Plasma glucose levels throughout the day and HbA1c interrelationships in type 2 diabetes. Implications for treatment and monitoring of metabolic control. Diabetes Care 2001, 24:2023-2029.
22. Cavalot F., Pagliarino A., Valle M., Di Martino L., Bonomo K., Massucco P., et al. Postprandial blood glucose predicts cardiovascular events and all-cause mortality in type 2 diabetes in a 14-year follow-up: lessons from the San Luigi Gonzaga Diabetes Study. Diabetes Care 2011, 34:2237-2243.
23. Muggeo M., Zoppini G., Bonora E., Brun E., Bonadonna R.C., Moghetti P., et al. Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients: the Verona Diabetes Study. Diabetes Care 2000, 23:45-50.
24. Goto A., Arah O.A., Goto M., Terauchi Y., Noda M. Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis. BMJ 2013, 347:f4533.
25. Svensson A.M., McGuire D.K., Abrahamsson P., Dellborg M. Association between hyper- and hypoglycaemia and 2 year all-cause mortality risk in diabetic patients with acute coronary events. Eur Heart J 2005, 26:1255-1261.
26. Zoungas S., Patel A., Chalmers J., de Galan B.E., Li Q., Billot L., et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010, 363:1410-1418. ADVANCE Collaborative Group.
27. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005, 54:1615-1625.
28. Reusch J.E. Diabetes, microvascular complications, and cardiovascular complications: what is it about glucose?. J Clin Invest 2003, 112:986-988.
29. Quagliaro L., Piconi L., Assaloni R., Martinelli L., Motz E., Ceriello A. Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)H-oxidase activation. Diabetes 2003, 52:2795-2804.
30. Azuma K., Kawamori R., Toyofuku Y., Kitahara Y., Sato F., Shimizu T., et al. Repetitive fluctuations in blood glucose enhance monocyte adhesion to the endothelium of rat thoracic aorta. Arterioscler Thromb Vasc Biol 2006, 26:2275-2280.
31. Monnier L., Mas E., Ginet C., Michel F., Villon L., Cristol J.P., et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006, 295:1681-1687.
32. Torimoto K., Okada Y., Mori H., Tanaka Y. Relationship between fluctuations in glucose levels measured by continuous glucose monitoring and vascular endothelial dysfunction in type 2 diabetes mellitus. Cardiovasc Diabetol 2013, 12:1-7.
33. Desouza C., Salazar H., Cheong B., Murgo J., Fonseca V. Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring. Diabetes Care 2003, 26:1485-1489.
34. Wright R.J., Frier B.M. Vascular disease and diabetes: is hypoglycaemia an aggravating factor?. Diabetes Metab Res Rev 2008, 24:353-363.
35. The University Group Diabetes Program A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. Diabetes 1970, 19(Suppl. 2):747-830.
36. UK Prospective Diabetes Study (UKPDS) Group Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853.
37. UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998, 352:854-865.
38. Holman R.R., Paul S.K., Berthel M.A., Mattjews D.R., Neil H.A. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577-1589.
39. Gerstein H.C., Miller M.E., Byington R.P., Goff D.C., Bigger J.T., Buse J.B., et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545-2559. Action to Control Cardiovascular Risk in Diabetes Study Group.
40. Patel A., MacMahon S., Chalmers J., Neal B., Billot L., Woodward M., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572. ADVANCE Collaborative Group.
41. Duckworth W., Abraira C., Moritz T., Reda D., Emanuele N., Reaven P.D., et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009, 360:129-139. VADT Investigators.
42. Hayward R.A., Reaven P.D., Wiitala W.L., Bahn G.D., Reda D.J., Ge L., et al. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015, 372:2197-2206. VADT Investigators.
43. Gerstein H.C., Bosch J., Dagenais G.R., Díaz R., Jung H., Maggioni A.P., et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012, 367:319-328. ORIGIN Trial Investigators.
44. Ray K.K., Seshasai S.R., Wijesuriya S., Sivakumaran R., Nethercott S., Preiss D., et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomized controlled trials. Lancet 2009, 373:1765-1772.
45. Boussageon R., Bejan-Angoulvant T., Saadatian-Elahi M., Lafont F., Bergeonneau C., Kassai B., et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death and microvascular events in type 2 diabetes: meta-analysis of randomized controlled trials. BMJ 2011, 343:d4169.
46. Kelly T.N., Bazzano L.A., Fonseca V.A., Thethi T.K., Reynolds K., He J. Systematic review: glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med 2009, 151:394-403.
47. Inzucchi S.E., Bergenstal R.M., Buse J.B., Diamant M., Ferrannini E., Nauk M., et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Diabetes Care 2012, 35:1364-1379.
48. Strain W.D., Lukashevich V., Kothny W., Hoellinger M.J., Paldanius P.M. Individualized treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or alone therapy (INTERVAL): a 24 week, randomized, double-blind, placebo-controlled study. Lancet 2013, 382:409-416.
49. Del Prato S. Megatrials in type 2 diabetes. From excitement to frustration?. Diabetologia 2009, 52:1219-1226.
50. Pozzilli P., Strollo R., Bonora E. One size does not fit all glycemic targets for type 2 diabetes. J Diabetes Invest 2014, 5:134-141.
51. Food and Drug Administration, Center for Drug Evaluation and Research Guidance for industry: diabetes mellitus-evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes 2008, U.S. Department of Health and Human Services.
52. Holst J.J., Vilsbøll T., Deacon C.F. The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol 2009, 297:127-136.
53. Nauck M., Stockmann F., Ebert R., Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin dependent) diabetes. Diabetologia 1986, 29:46-52.
54. Deacon C.F. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab 2011, 13:7-18.
55. Karagiannis T., Paschos P., Paletas K., Matthews D.R., Tsapas A. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ 2012, 344:e1369.
56. Del Prato S., Barnett A.H., Huisman H., Neubacher D., Woerle H.J., Dugi K.A. Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab 2011, 13:258-267.
57. Guerci B., Monnier L., Serusclat P., Petit C., Valensi P., Huet D., et al. Continuous glucose profile with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study. Diabetes Metab 2012, 38:359-366.
58. Sakamoto M., Nishimura R., Irako T., Tsujino D., Ando K., Utsonomiya K. Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J-Victoria study). Cardiovasc Diabetol 2012, 11:92-98.
59. Ahren B., Schweizer A., Dejager S., Dunning B.E., Nilsson P.M., Persson M., et al. Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes. J Clin Endocrinol Metab 2009, 94:1236-1243.
60. Zhang Y., Hong J., Chi J., Gu W., Ning G., Wang W. Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas - a meta-analysis from randomized clinical trials. Diabetes Metab Res Rev 2014, 30:241-256.
61. Monami M., Dicembrini I., Mannucci E. Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2014, 16:48-56.
62. Egan A.G., Blind E., Dunder K., de Graeff P.A., Hummer B.T., Bourcier T., et al. Pancreatic safety of incretin-based drug. FDA and EMA Assessment. N Engl J Med 2014, 370:794-797.
63. Drucker D.J., Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368:1696-1705.
64. Chrysant S.G., Chrysant G.S. Clinical implications of cardiovascular preventing pleiotropic effects of dipeptidyl peptidase-4 inhibitors. Am J Cardiol 2012, 109:1681-1685.
65. Monami M., Lamanna C., Desideri C.M., Mannucci E. DPP-4 inhibitors and lipids: systematic review and meta-analysis. Adv Ther 2012, 29:14-25.
66. Matikainen N., Mänttäri S., Schweizer A., Ulvestad A., Mills D., Dunning B.E., et al. Vildagliptin therapy reduces post-prandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia 2006, 49:2049-2057.
67. Noda Y., Miyoshi T., Oe H., Ohno Y., Nakamura K., Toh N., et al. Alogliptin ameliorates postprandial lipemia and postprandial endothelial dysfunction in non-diabetic subjects: a preliminary report. Cardiovasc Diabetol 2013, Jan 9, 12:8. 10.1186/1475-2840-12-8.
68. Eliasson B., Möller-Goede D., Eeg-Olofsson K., Wilson C., Cederholm J., Fleck P., et al. Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study. Diabetologia 2012, 55:915-925.
69. Koren S., Shemesh-Bar L., Tirosh A., Peleg R.K., Berman S., Hamad R.A., et al. The effect of sitagliptin versus glibenclamide on arterial stiffness, blood pressure, lipids, and inflammation in type 2 diabetes mellitus patients. Diabetes Technol Ther 2012, 14:561-567.
70. Scheen A.J. Cardiovascular effects of gliptins. Nat Rev Cardiol 2013, 10:73-84.
71. Shah Z., Pineda C., Kampfrath T., Maiseyeu A., Ying Z., Racoma I., et al. Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways. Vasc Pharmacol 2011, 55:2-9.
72. Mason R.P., Jacob R.F., Kubant R., Ciszewski A., Corbalan J.J., Malinski T. Dipeptidyl peptidase-4 inhibition with saxagliptin enhanced nitric oxide release and reduced blood pressure and sICAM-1 levels in hypertensive rats. J Cardiovasc Pharmacol 2012, 60:467-473.
73. Liu L., Liu J., Wong W.T., Tian X.Y., Lau C.W., Wang Y.X., et al. Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism. Hypertension 2012, 60:833-841.
74. Matsubara J., Sugiyama S., Akiyama E., Iwashita S., Kurokawa H., Ohba K., et al. Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes. Circ J 2013, 77:1337-1344.
75. Hage C., Brismar K., Lundman P., Norhammar A., Rydén L., Mellbin L. The DPP-4 inhibitor sitagliptin and endothelial function in patients with acute coronary syndromes and newly detected glucose perturbations: a report from the BEGAMI study. Diab Vasc Dis Res 2014, 11:290-293.
76. Ayaori M., Iwakami N., Uto-Kondo H., Sato H., Sasaki M., Komatsu T., et al. Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients. J Am Heart Assoc 2013 Jan 28, 2:e003277.
77. Nakamura K., Oe H., Kihara H., Shimada K., Fukuda S., Watanabe K., et al. DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study. Cardiovasc Diabetol 2014 Jul 30, 13(1):110.
78. Van Poppel P.C.M., Netea M.G., Smits P., Tack C.J. Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes. Diabetes Care 2011, 34:2072-2077.
79. Tremblay A.J., Lamarche B., Deacon C.F., Weisnagel S.J., Couture P. Effects of sitagliptin therapy on markers of low-grade inflammation and cell adhesion molecules in patients with type 2 diabetes. Metabolism 2014, 63:1141-1148.
80. Cakirca M., Karatoprak C., Zorlu M., Kiskac M., Kanat M., Cikrikcioglu M.A., et al. Effect of vildagliptin add-on treatment to metformin on plasma asymmetric dimethylarginine in type 2 diabetes mellitus patients. Drug Des Devel Ther 2014, 8:239-243.
81. Satoh-Asahara N., Sasaki Y., Wada H., Tochiya M., Iguchi A., Nakagawachi R., et al. A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients. Metabolism 2013, 62:347-351.
82. Makdissi A., Ghanim H., Vora M., Green K., Abuaysheh S., Chaudhuri A., et al. Sitagliptin exerts an antinflammatory action. J Clin Endocrinol Metab 2012, 97:3333-3341.
83. Lim S., Choi S.H., Shin H., Cho B.J., Park H.S., Ahn B.Y., et al. Effect of a dipeptidyl peptidase-IV inhibitor, des-fluoro-sitagliptin, on neointimal formation after balloon injury in rats. PLoS One 2012, 7:e35007.
84. Kröller-Schön S., Knorr M., Hausding M., Oelze M., Schuff A., Schell R., et al. Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition. Cardiovasc Res 2012, 96:140-149.
85. Ta N.N., Schuyler C.A., Li Y., Lopes-Virella M.F., Huang Y. DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice. J Cardiovasc Pharmacol 2011, 58:157-166.
86. Nistala R., Habibi J., Aroor A., Sowers J.R., Hayden M.R., Meuth A., et al. DPP4 inhibition attenuates filtration barrier injury and oxidant stress in the zucker obese rat. Obesity 2014, 22:2172-2179.
87. Bao W., Morimoto K., Hasegawa T., Sasaki N., Yamashita T., Hirata K., et al. Orally administered dipeptidyl peptidase-4 inhibitor (alogliptin) prevents abdominal aortic aneurysm formation through an antioxidant effect in rats. J Vasc Surg 2014, 59:1098-1108.
88. Matsui T., Nishino Y., Takeuchi M., Yamagishi S. Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis. Pharmacol Res 2011, 63:383-388.
89. Ishibashi Y., Matsui T., Takeuchi M., Yamagishi S. Sitagliptin augments protective effects of GLP-1 against advanced glycation end product receptor axis in endothelial cells. Horm Metab Res 2011, 43:731-734.
90. Ishibashi Y., Matsui T., Maeda S., Higashimoto Y., Yamagishi S. Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor. Cardiovasc Diabetol 2013, 12:125. 10.1186/1475-2840-12-125.
91. Rizzo M.R., Marfella R., Barbieri M., Paolisso G. Reduction of oxidative stress and of inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes. Diabetes Care 2012, 35:2076-2082.
92. Shah Z., Kampfrath T., Deiuliis J.A., Zhong J., Pineda C., Ying Z., et al. Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation 2011, 124:2338-2349.
93. Ta N.N., Li Y., Schuyler C.A., Lopes-Virella M.F., Huang Y. DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes. Atherosclerosis 2010, 213:429-435.
94. Akita K., Isoda K., Shimada K., Daida H. Dipeptidyl-peptidase-4 inhibitor, alogliptin, attenuates arterial inflammation and neointimal formation after injury in low-density lipoprotein (LDL) receptor-deficient mice. J Am Heart Assoc 2015, 4:e001469.
95. Takai S., Sakonjo H., Jin D. Significance of vascular dipeptidyl peptidase-4 inhibition on vascular protection in Zucker diabetic fatty rats. J Pharmacol Sci 2014, 125:386-393.
96. Yamagishi S., Ishibashi Y., Ojima A., Sugiura T., Matsui T. Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor, decreases serum uric acid levels in type 2 diabetic patients partly by suppressing xanthine oxidase activity. Int J Cardiol 2014, 176:550-552.
97. Fadini G.P., Boscaro E., Albiero M., Menegazzo L., Frison V., de Kreutzenberg S., et al. The oral dipeptidyl dipeptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1 alpha. Diabetes Care 2010, 33:1607-1609.
98. Poncina N., Albiero M., Menegazzo L., Cappellari R., Avogaro A., Fadini G.P. The dipeptidyl peptidase-4 inhibitor Saxagliptin improves function of circulating pro-angiogenic cells from type 2 diabetic patients. Cardiovasc Diabetol 2014 May 14, 13:92. 10.1186/1475-2840-13-92.
99. Ishii M., Shibata R., Kondo K., Kambara T., Shimizu Y., Tanigawa T., et al. Vildagliptin stimulates endothelial cell network formation and ischemia-induced revascularization via an endothelial nitric oxide synthase-dependent mechanism. J Biol Chem 2014, 289:27235-27245. pii: jbc.M114.557835.
100. Gupta A.K., Verma A.K., Kailashiya J., Singh S.K., Kumar N. Sitagliptin: antiplatelet effect in diabetes and healthy volunteers. Platelets 2012, 23:565-570.
101. Hu Y., Liu H., Simpson R.W., Dear A.E. GLP-1 dependent and independent effects and molecular mechanisms of a dipeptidyl peptidase-4 inhibitor in vascular endothelial cells. Mol Biol Rep 2013, 40:2273-2279.
102. Khan S., Khan S., Imran M., Pillai K.K., Akhtar M., Najmi A.K. Effects of pioglitazone and vildagliptin on coagulation cascade in diabetes mellitus-targeting thrombogenesis. Expert Opin Ther Targets 2013, 17:627-639.
103. Forst T., Anastassiadis E., Diessel S., Löffler A., Pfützner A. Effect of linagliptin compared with glimepiride on postprandial glucose metabolism, islet cell function and vascular function parameters in patients with type 2 diabetes mellitus receiving ongoing metformin treatment. Diabetes Metab Res Rev 2014, 30:582-589.
104. Berndt-Zipfel C., Michelson G., Dworak M., Mitry M., Loffler A., Pfutzner A., et al. Vildagliptin in addition to metformin improves retinal blood flow and erythrocyte deformability in patients with type 2 diabetes mellitus - results from an exploratory study. Cardiovasc Diabetol 2013, 12:59. 10.1186/1475-2840-12-59.
105. Ishikawa S., Shimano M., Watarai M., Koyasu M., Uchikawa T., Ishii H., et al. Impact of sitagliptin on carotid intima-media thickness in patients with coronary artery disease and impaired glucose tolerance or mild diabetes mellitus. Am J Cardiol 2014, 114:384-388.
106. Barbieri M., Rizzo M.R., Marfella R., Boccardi V., Esposito A., Pansini A., et al. Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-4 inhibitors. Atherosclerosis 2013, 227:349-354.
107. Read P.A., Kahn F.Z., Heck P.M., Hoole S.P., Dutka D.P. DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease. Circ Cardiovasc Imaging 2010, 3:195-201.
108. McCormick L.M., Kydd A.C., Read P.A., Ring L.S., Bond S.J., Hoole S.P., et al. Chronic dipeptidyl peptidase-4 inhibition with sitagliptin is associated with sustained protection against ischemic left ventricular dysfunction in a pilot study of patients with type 2 diabetes mellitus and coronary artery disease. Circ Cardiovasc Imaging 2014, 7:274-281.
109. Witteles R.M., Keu K.V., Quon A., Tavana H., Fowler M.B. Dipeptidyl peptidase 4 inhibition increases myocardial glucose uptake in nonischemic cardiomyopathy. J Card Fail 2012, 18:804-809.
110. Rahmi R.M., Uchida A.H., Rezende P.C., Lima E.G., Garzillo C.L., Favarato D., et al. Effect of hypoglycemic agents on ischemic preconditioning in patients with type 2 diabetes and symptomatic coronary artery disease. Diabetes Care 2013, 36:1654-1665.
111. Gallwitz B., Rosenstock J., Rauch T., Bhattacharya S., Patel S., von Eynatten M., et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet 2012, 380:475-483.
112. Williams-Herman D., Engel S.S., Round E., Johnson J., Golm G.T., Guo H., et al. Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocr Disord 2010; Apr 22, 10:7. 10.1186/1472-6823-10-7.
113. Schweizer A., Dejager S., Foley J.E., Couturier A., Ligueros-Saylan M., Kothny W. Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large phase III type 2 diabetes population. Diabetes Obes Metab 2010, 12:485-494.
114. Frederich R., Alexander J.H., Fiedorek F.T., Donovan M., Berglind N., Harris S., et al. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med 2010, 122:16-27.
115. Johansen O.E., Neubacher D., von Eynatten M., Patel S., Woerle H.J. Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme. Cardiovasc Diabetol 2012, 11:3. 10.1186/1475-2840-11-3.
116. White W.B., Pratley R., Fleck P., Munsaka M., Hisada M., Wilson C., et al. Cardiovascular safety of the dipeptidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus. Diabetes Obes Metab 2013, 15:668-673.
117. Monami M., Dicembrini I., Martelli D., Mannucci E. Safety of dipeptidyl peptidase 4 inhibitors: a meta-analysis of randomized clinical trials. Curr Med Res Opin 2011, 27:57-64.
118. Monami M., Ahren B., Dicembrini I., Mannucci E. Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2013, 15:112-120.
119. Morgan C.L., Mukherjee J., Jenkins-Jones S., Holden S.E., Currie C.J. Combination therapy with metformin plus sulphonylureas versus metformin plus DPP-4 inhibitors: association with major adverse cardiovascular events and all-cause mortality. Diabetes Obes Metab 2014, 16:977-983.
120. Scirica B.M., Bhatt D.L., Braunwald E., Steg P.G., Davidson J., Hirshberg B., et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013, 369:1317-1326. SAVOR-TIMI 53 Steering Committee and Investigators.
121. White W.B., Cannon C.P., Heller S.R., Nissen S.E., Bergenstal R.M., Bakris G.L., et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013, 369(14):1327-1335. EXAMINE Investigators.
122. Zannad F., Cannon C.P., Cushman W.C., Bakris G.L., Menon V., Perez A.T., et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet 2015, 385:2067-2076. EXAMINE Investigators.
123. Monami M., Dicembrini I., Mannucci E. Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 2014, 24:689-697.
124. Krum H., Lukashevich V., Bolli G.B., Kozlovski P., Kothny W., Ponikowski P. No significant difference in risk of heart failure hospitalization with vildagliptin in diabetic patients with systolic chronic heart failure: VIVIDD study. Diabetes 2014, 63(Suppl. 1). (abstract ADA 2014).
125. Green J.B., Bethel M.A., Armstrong P.W., Buse J.B., Engel S.S., Garg J., et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015, 373:232-242. TECOS Study Group.
126. Rosenstock J., Marx N., Kahn S.E., Zinman B., Kastelein J.J., Lachin J.M., et al. Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial. Diab Vasc Dis Res 2013, 10:289-301.
127. Kooy A., de Jager J., Lehert P., Bets D., Wulffelè M.G., Donker A.J., et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med 2009, 169:616-625.
128. Morgan C.L., Mukherjee J., Jenkins-Jones S., Holden S.E., Currie C.J. Association between first-line monotherapy with sulphonylurea versus metformin and risk of all-cause mortality and cardiovascular events: a retrospective, observational study. Diabetes Obes Metab 2014, 16:957-962.
129. Bannister C.A., Holden S.E., Jenkins-Jones S., Morgan C.L., Halcox J.P., Schernthaner G., et al. Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls. Diabetes Obes Metab 2014, 16:1165-1173.
130. Boussageon R., Supper I., Bejan-Angoulvant T., Kellou N., Cucherat M., Boissel J.P., et al. Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials. PLoS Med 2012, 9:e1001204. Epub 2012 Apr 10. 10.1371/journal.pmed.1001204.
131. Hemmingsen B., Christensen L.L., Wetterslev J., Vaag A., Gluud C., Lund S.S., et al. Comparison of metformin and insulin versus insulin alone for type 2 diabetes: systematic review of randomised clinical trials with meta-analyses and trial sequential analyses. BMJ 2012, 344:e1771.
132. Turner R.C., Cull C.A., Frighi V., Holman R.R. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999, 281:2005-2012.
133. Liu S.C., Tu Y.K., Chien M.N., Chien K.L. Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis. Diabetes Obes Metab 2012, 14:810-820.
134. Gross J.L., Kramer C.K., Leitão C.B., Hawkins N., Viana L.V., Schaan B.D., et al. Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis. Ann Intern Med 2011, 154:672-679. Diabetes and Endocrinology Meta-analysis Group (DEMA).
135. Rao A.D., Kuhadiya N., Reynolds K., Fonseca V.A. Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies. Diabetes Care 2008, 31:1672-1678.
136. Lamanna C., Monami M., Marchionni N., Mannucci E. Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2011, 13:221-228.
137. Vaccaro O., Masulli M., Bonora E., Del Prato S., Nicolucci A., Rivellese A.A., et al. The TOSCA.IT trial: a study designed to evaluate the effect of pioglitazone versus sulfonylureas on cardiovascular disease in type 2 diabetes. Diabetes Care 2012, 35:e82. TOSCA.IT Study Group.
138. Johnson J.A., Majumdar S.R., Simpson S.H., Toth E.L. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 2002, 25:2244-2248.
139. Evans J.M., Ogston S.A., Emslie-Smith A., Morris A.D. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 2006, 49:930-936.
140. Tzoulaki I., Molokhia M., Curcin V., Little M.P., Millett C.J., Ng A., et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 2009, 339:b4731.
141. Khalangot M., Tronko M., Kravchenko V., Kovtun V. Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study. Diabetes Res Clin Pract 2009, 86:247-253.
142. Monami M., Luzzi C., Lamanna C., Chiasserini V., Addante F., Desideri C.M., et al. Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin. Diabetes Metab Res Rev 2006, 22:477-482.
143. Monami M., Genovese S., Mannucci E. Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2013, 15:938-953.
144. Forst T., Hanefeld M., Jacob S., Moeser G., Schwenk G., Pfutzener A., et al. Association of sulphonylurea treatment with all-cause and cardiovascular mortality: a systematic review and meta-analysis of observational studies. Diabetes Vasc Dis Res 2013, 10:302-314.
145. Phung O.J., Schwartzman E., Allen R.W., Engel S.S., Rajpathak S.N. Sulphonylureas and risk of cardiovascular disease: systematic review and meta-analysis. Diabet Med 2013, 30:1160-1171.
146. Abdelmoneim A.S., Hasenbank S.E., Seubert J.M., Brocks D.R., Light P.E., Simpson S.H. Variations in tissue selectivity amongst insulin secretagogues: a systematic review. Diabetes Obes Metab 2012, 14:130-138.
147. Ashcroft F.M., Gribble F.M. Tissue-specific effects of sulfonylureas: lessons from studies of cloned K(ATP) channels. J Diabetes Complications 2000, 14:192-196.
148. Engbersen R., Masereeuw R., van Gestel M.A., Siero H.L., Moons M.M., Smits P., et al. Differential effects of sulfonylurea derivatives on vascular ATP-sensitive potassium channels. Eur J Pharmacol 2012, 681:75-79.
149. Tomai F., Crea F., Gaspardone A., Versaci F., De Paulis R., Penta de Peppo A., et al. Ischemic preconditioning during coronary angioplasty is prevented by glibenclamide, a selective ATP-sensitive K+ channel blocker. Circulation 1994, 90:700-705.
150. Scognamiglio R., Avogaro A., Vigili de Kreutzenberg S., Negut C., Palisi M., Bagolin E., et al. Effects of treatment with sulphonylurea drugs or insulin on ischemia-induced myocardial disfunction in type 2 diabetes. Diabetes 2002, 51:808-812.
151. Bennett W.L., Maruthur N.M., Singh S., Segal J.B., Wilson L.M., Chatterjee R., et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med 2011, 154:602-613.
152. Tessier D., Dawson K., Tétrault J.P., Bravo G., Meneilly G.S. Glibenclamide vs gliclazide in type 2 diabetes of the elderly. Diabet Med 1994, 11:974-980.
153. Schernthaner G., Grimaldi A., Di Mario U., Drzewoski J., Kempler P., Kvapil M., et al. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest 2004, 34:535-542.
154. Gangji A.S., Cukierman T., Gernstein H.C., Goldsmith C.H., Clase C.M. A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care 2007, 30:389-394.
155. Simpson S.H., Lee J., Choi S., Vandermeer B., Abdelmoneim A.S., Featherstone T.R. Mortality risk among sulfonylureas: a systematic review and network. Meta-analysis. Lancet Diabetes Endocrinol 2015, 3:43-51.
156. Loubani M., Fowler A., Standen N.B., Galiñanes M. The effect of gliclazide and glibenclamide on preconditioning of the human myocardium. Eur J Pharmacol 2005, 16(515):142-149.
157. Hemmingsen B., Schroll J.B., Lund S.S., Wetterslev J., Gluud C., Vaag A., et al. Sulphonylurea monotherapy for patients with type 2 diabetes mellitus. Cochrane Database Syst Rev 2013 Apr 30, 4.
158. Schramm T.K., Gislason G.H., Vaag A., Rasmussen J.N., Folke F., Hansen M.L., et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J 1900-1908, 201:32.
159. Holman R.R., Haffner S.M., McMurray J.J., Bethel M.A., Holzhauer B., Hua T.A., et al. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 2010, 362:1463-1476. NAVIGATOR Study Group.
160. Dormandy J.A., Charbonnel B., Eckland D.J., Erdmann E., Massi-Benedetti M., Moules I.K., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomised controlled trial. Lancet 2005, 366:1279-1289. PROactive investigators.
161. Erdmann E., Dormandy J.A., Charbonnel B., Massi-Benedetti M., Moules I.K., Skene A.M. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05). Study J Am Coll Cardiol 2007, 49:1772-1780. PROactive Investigators.
162. Wilcox R., Bousser M.G., Betteridge D.J., Schernthaner G., Pirags V., Kupfer S., et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial in macroVascular Events 04. Stroke 2007, 38:865-873. PROactive Investigators.
163. Mazzone T., Meyer P.M., Feinstein S.B., Davidson M.H., Kondos G.T., D'Agostino R.B., et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. J Am Med Assoc 2006, 296:2572-2581.
164. Nissen S.E., Nicholls S.J., Wolski K., Nesto R., Kupfer S., Perez A., et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. J Am Med Assoc 2008, 299:1561-1573. PERISCOPE Investigators.
165. Morgan C.L., Poole C.D., Evans M., Barnett A.H., Jenkins-Jones S., Currie C.J. What next after metformin? A retrospective evaluation of the outcome of second-line, glucose-lowering therapies in people with type 2 diabetes. J Clin Endocrinol Metab 2012, 97:4605-4612.
166. Lincoff A.M., Wolski K., Nicholls S.J., Nissen S.E. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. J Am Med Assoc 2007, 298:1180-1188.
167. Loke Y.K., Kwok C.S., Singh S. Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. BMJ 2011, 342:d1309.
168. Charbonnel B.H., Matthews D.R., Schernthaner G., Hanefeld M., Brunetti P. A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial. Diabet Med 2005, 22:399-405. QUARTET Study Group.
169. Chiquette E., Ramirez G., Defronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 2004, 164:2097-2104.
170. Bilik D., McEwen L.N., Brown M.B., Pomeroy N.E., Kim C., Asao K., et al. Thiazolidinediones and fractures: evidence from translating research into action for diabetes. J Clin Endocrinol Metab 2010, 95:4560-4565.
171. Azoulay L., Yin H., Filion K.B., Assayag J., Majdan A., Pollak M.N., et al. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. BMJ 2012, 30:344:e3645.
172. Van de Laar F.A., Lucassen P.L., Akkermans R.P., Van de Lisdonk E.H., Rutten G.E., Van Weel C. Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005; Apr 18, 2:CD003639.
173. Chiasson J.L., Josse R.G., Gomis R., Hanefeld M., Karasik A., Laakso M. STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. J Am Med Assoc 2003, 290:486-494.
174. Hanefeld M., Cagatay M., Petrowitsch T., Neuser D., Petzinna D., Rupp M. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 2004, 25:10-16.
175. Vasilakou D., Karagiannis T., Athanasiadou E., Mainou M., Liakos A., Bekiari E., et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 2013, 159:262-274.
176. Baker W.L., Smyth L.R., Riche D.M., Bourret E.M., Chamberlin K.W., White W.B. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens 2014, 8:262-275.
177. Dziuba J., Alperin P., Racketa J., Iloeje U., Goswami D., Hardy E., et al. Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes. Diabetes Obes Metab 2014, 16:628-635.
178. Neal B., Perkovic V., de Zeeuw D., Mahaffey K.W., Fulcher G., Stein P., et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)-a randomized placebo-controlled trial. Am Heart J 2013, 166:217-223.
179. Zinman B., Wanner C., Lachin J.M., Fitchett D., Bluhmki E., Hantel S., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015, 373:2117-2128. EMPA-REG OUTCOME Investigators.